Drug Profile
Research programme: antibody therapeutics - Ferring Pharmaceuticals
Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator Ferring Pharmaceuticals
- Developer Ferring Pharmaceuticals; Ligand Pharmaceuticals
- Class Antiulcers; Bispecific antibodies; Digestion aids; Monoclonal antibodies; Urologics
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Female genital diseases; Gastrointestinal disorders; Genitourinary disorders
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Female-genital-diseases in Switzerland (Parenteral)
- 28 Feb 2022 No recent reports of development identified for research development in Gastrointestinal-disorders in Switzerland (Parenteral)
- 28 Feb 2022 No recent reports of development identified for research development in Genitourinary-disorders in Switzerland (Parenteral)